Clinical trial
A Randomized, Multi-center, Phase II Study of the Safety, Tolerability, and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema With Involvement of the FoveAL Center (the iDEAL Study)
NCT01565148 is registered in ClinicalTrials.gov with Johns Hopkins University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Multi-center, Phase II Study of the Safety, Tolerability, and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema With Involvement of the FoveAL Center (the iDEAL Study)
- Lead sponsor
- Johns Hopkins University
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- February 29, 2012
- Completion date
- October 31, 2014
- Enrollment
- 185 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
diabetic macular edema